Front Page News
2016 Research Year-in-Review: An Historic Year for Our Community
This has been an historic year for the SMA community. On December 23, the FDA announced its approval of Spinraza, the first-ever approved treatment for […]
Read More ›Biogen Resources for the SMA Community
Biogen has provided the following update on resources they have made available for the SMA community: Biogen recently announced that the U.S. Food and Drug […]
Read More ›Join Us for an Upcoming Webcast about SPINRAZA TM (nusinersen)
Please join Cure SMA, MDA and representatives from Biogen to learn more about SPINRAZA™ (nusinersen). As you know, SPINRAZA recently received FDA approval in the […]
Read More ›Biogen Provides Community Statement and Q&A on the Approval of Spinraza for SMA
Biogen provided the following statement on the approval of Spinraza for SMA: Dear Members of the SMA Community, Today, the SMA community achieved a goal […]
Read More ›Ionis Pharmaceuticals Issues Community Statement on the Approval of Spinraza
Ionis Pharmaceuticals has issued the following community statement on the approval of Spinraza for SMA: Dear Members of the SMA Community, Today is a historic […]
Read More ›FDA Approves Spinraza for SMA
On December 23, the FDA announced that it has approved SpinrazaTM (nusinersen) to treat spinal muscular atrophy, making it the first-ever FDA-approved therapy for SMA. […]
Read More ›Cure SMA Participates in a Special FDA Listening Session
Last week, Cure SMA participated in a listening session with FDA Commissioner Robert M. Califf, MD, MACC. The FDA organized the listening session in order […]
Read More ›Cure SMA Announces Additional Conference Support for Newly Diagnosed Families
Thanks to the generous funding provided by the Erin Trainor Memorial Fund, Cure SMA is now offering additional support for newly diagnosed families to attend […]
Read More ›SMA Community Conducts Outreach Visits with Members of Congress
On November 30, members of the SMA community met with 17 different legislative offices— eight from the Senate and nine from the House of Representatives. […]
Read More ›The Lancet Publishes Data from Phase 2, Open-Label Trial of Spinraza (Nusinersen) in Infants
Today, Lancet published results from the Phase 2, open-label trial of nusinersen (Spinraza) in infants. This trial initiated in 2013, and patients continue to receive […]
Read More ›